Answers are grounded in this paper and cite their sources.
Fingolimod is a selective sphingosine-1-phosphate (S1P) receptor modulator approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) as monotherapy, in cases of first-line treatment failure, or as a first option in aggressive forms. The appearance of neoplasms is among the infrequent side effects of treatment. This is a case report on an MS patient treated with Fingolimod who developed pulmonary signet-ring cell adenocarcinoma of the lung and features a discussion of the drug’s possible involvement in the development of these types of neoplasms.
No takes yet. Share an insight, caveat, or question.
Imbroda et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: